文献速递皮肤肿瘤

三维全身摄影在高危黑色素瘤患者中的随机临床试验

3D Total-Body Photography in Patients at High Risk for Melanoma: A Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2025-01-01

这项随机临床试验在澳大利亚布里斯班纳入314例高危黑色素瘤患者,比较常规护理与常规护理加每6个月三维全身摄影和序贯数字皮肤镜成像(通过远程皮肤病学)的临床结局。结果显示干预组切除或活检病变数显著更高,但检出黑色素瘤数更少,1年随访时黑色素瘤发生率较低但无统计学显著性。

要点

  • 干预组检出黑色素瘤24例(35%),对照组43例(64%)。
  • 1年随访时干预组黑色素瘤发生率较低但无统计学显著性(0.08 vs 0.16)。

核心结论

  • 在远程皮肤病学设置中,常规护理加三维全身摄影和序贯数字皮肤镜成像增加了皮肤切除和活检的数量与比率。

研究设计与样本

  • 随机临床试验,在澳大利亚布里斯班的研究医院进行,纳入314例成人高危黑色素瘤患者,干预组158例,对照组156例。

主要发现

  • 共进行1527次切除,干预组905次,对照组622次;67次(4%)病理确诊为黑色素瘤,402次(26%)为角质形成细胞癌。
  • 干预组检出黑色素瘤24例(35%),对照组43例(64%);发生率分别为2.03(95%CI 1.30-3.02)和3.62(95%CI 2.62-4.88)。
  • 1年随访时,干预组人均黑色素瘤发生率为0.08(95%CI 0.03-0.13),对照组为0.16(95%CI 0.08-0.25),无统计学显著性。
  • 1年随访时,干预组人均角质形成细胞癌为0.86(95%CI 0.55-1.16),对照组为0.42(95%CI 0.24-0.59);人均切除或活检为2.01(95%CI 1.50-2.51) vs 1.39(95%CI 0.98-1.82)。

临床怎么用

  • 在高危黑色素瘤患者的远程皮肤病学随访中,增加三维全身摄影和序贯数字皮肤镜成像可提高皮肤病变的切除和活检率。
  • 需进一步研究比较远程皮肤病学与常规护理,并探索人工智能是否能改善远程皮肤病学结局。

局限性

  • 研究为单中心随机临床试验,需要更大规模、多设置、更多远程皮肤病学医生的研究。
  • 研究比较的是常规护理加远程皮肤病学干预与常规护理,而非远程皮肤病学与常规护理的直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Three-dimensional (3D) total-body photography (TBP) can support clinicians in monitoring and identifying changes to skin lesions in patients at high risk of melanoma. OBJECTIVE: To assess clinical outcomes between patients at high risk of melanoma receiving usual clinical care compared with those receiving usual care plus 3D TBP and sequential digital dermoscopy imaging (SDDI) every 6 months via teledermatology. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted at a research hospital in Brisbane, Australia, from April 2018 to October 2021, with adult patients (≥18 years) at high risk of developing a primary or subsequent melanoma. Data analysis was conducted from March 2022 to June 2024. INTERVENTION: Usual care plus 3D-TBP in person and SDDI via teledermatology at baseline, 6, 12, 18, and 24 months. The control group continued usual care and completed online surveys every 6 months. MAIN OUTCOME MEASURES: Number and rates of excisions and/or biopsies of lesions suggestive of melanoma, and results of histopathologic testing. RESULTS: The analysis included 314 participants (mean [SD] age, 51.6 [12.8] years; 194 females [62%]) who completed all of the study procedures (158 in the intervention and 156 in the control). In all, 1527 excisions (905 intervention and 622 in the control) were performed among 226 participants (122 intervention and 104 controls), with 67 (4%) histopathologically confirmed as melanoma and 402 (26%) as keratinocyte cancer (KC). The mean (SD) number of lesions of any type excised per person was significantly higher in the intervention (5.73 [6.77]; 95% CI, 4.66-6.79) compared to the control group (3.99 [5.72]; 95% CI, 3.08-4.89; P = .02). Fewer melanomas were detected among the intervention group compared with the control (24 [35%] vs 43 [64%], respectively), and therefore, a lower incidence rate: 2.03 (95% CI, 1.30-3.02) vs 3.62 (95% CI, 2.62-4.88), respectively. After 1 year of follow-up, the intervention had a lower, but not statistically significant, rate of melanoma per person: 0.08 (95% CI, 0.03-0.13) compared with 0.16 (95% CI, 0.08-0.25) in the control; an average of 0.86 (95% CI, 0.55-1.16) vs 0.42 (95% CI, 0.24-0.59) KCs per person; and 2.01 (95% CI, 1.50-2.51) vs 1.39 (95% CI, 0.98-1.82) excisions or biopsies per person, respectively. CONCLUSIONS AND RELEVANCE: The results of this randomized clinical trial indicate that the addition of 3D-TPB and SDDI to usual care in a teledermatology setting without AI (artificial intelligence) increased the number and rate of skin excisions and biopsies performed. Further studies are required to compare teledermatology to usual care rather than adding it, and to study whether the use of AI can improve the teledermatology outcomes. Larger studies in multiple settings with a greater number of teledermatologists are needed. This study shows that conducting clinical trials in this setting is feasible. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12618000267257.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Soyer HP, Jayasinghe D, Rodriguez-Acevedo AJ, et al. 3D Total-Body Photography in Patients at High Risk for Melanoma: A Randomized Clinical Trial. JAMA Dermatol. 2025. PMID: 40136310. doi:10.1001/jamadermatol.2025.0211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。